KYVERNA THERAPEUTICS Share Price Today: Live Updates & Key Insights

KYVERNA THERAPEUTICS share price today is $7.93, up -7.03%. The stock opened at $8.3 against the previous close of $8.54, with an intraday high of $8.41 and low of $7.92.

KYVERNA THERAPEUTICS Share Price Chart

KYVERNA THERAPEUTICS

us-stock
To Invest in {{usstockname}}
us-stock

KYVERNA THERAPEUTICS Share Price Performance

$7.93 -0.0703(-7.03%) KYTX at 23 Mar 2026 01:54 PM Biotechnology
Lowest Today 7.92
Highest Today 8.41
Today’s Open 8.3
Prev. Close 8.54
52 Week High 13.67
52 Week Low 1.78
Day’s Range: Low 7.92 High 8.41
52-Week Range: Low 1.78 High 13.67
1 day return -
1 Week return -12.65
1 month return +0.63
3 month return -2.45
6 month return +20.85
1 year return +236.44
3 year return -
5 year return -
10 year return -

KYVERNA THERAPEUTICS Institutional Holdings

KYVERNA THERAPEUTICS Market Status

Strong Buy: 3

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

KYVERNA THERAPEUTICS Fundamentals

Market Cap 473.28 M

PB Ratio 3.3501

PE Ratio 0.0

Enterprise Value 307.16 M

Total Assets 304.65 M

Volume 1571693

KYVERNA THERAPEUTICS Company Financials

Annual Revenue FY23:0 0.0M

Annual Profit FY23:null 0.0M

Annual Net worth FY23:-60366000 -60.4M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-415000 -0.4M, Q2/2025:-515000 -0.5M, Q1/2025:-501000 -0.5M, Q3/2024:null 0.0M, Q2/2024:-530000 -0.5M

Quarterly Net worth Q3/2025:-36787000 -36.8M, Q2/2025:-42081000 -42.1M, Q1/2025:-44635000 -44.6M, Q3/2024:-34492000 -34.5M, Q2/2024:-28803000 -28.8M

About KYVERNA THERAPEUTICS & investment objective

Company Information Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Organisation Biotechnology

Employees 129

Industry Biotechnology

CEO Mr. Warner Biddle

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

KYVERNA THERAPEUTICS FAQs

What is the share price of KYVERNA THERAPEUTICS today?

The current share price of KYVERNA THERAPEUTICS is $7.93.

Can I buy KYVERNA THERAPEUTICS shares in India?

Yes, Indian investors can buy KYVERNA THERAPEUTICS shares by opening an international trading and demat account with Motilal Oswal.

How to buy KYVERNA THERAPEUTICS shares in India?

You can easily invest in KYVERNA THERAPEUTICS shares from India by:

Can I buy fractional shares of KYVERNA THERAPEUTICS?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of KYVERNA THERAPEUTICS?

KYVERNA THERAPEUTICS has a market cap of $473.28 M.

In which sector does KYVERNA THERAPEUTICS belong?

KYVERNA THERAPEUTICS operates in the Biotechnology sector.

What documents are required to invest in KYVERNA THERAPEUTICS stocks?

To invest, you typically need:

What is the PE and PB ratio of KYVERNA THERAPEUTICS?

The PE ratio of KYVERNA THERAPEUTICS is N/A and the PB ratio is 3.35.